Loading...

CYCC CYCLACEL PHARMACEUTICALS INC Delisting Actions 8-K Filing

CYCL

CYCC

CYCLACEL PHARMACEUTICALS INC

(CYCC)

2024 8-K

Show Summary

Show Summary

Increase in Dividend Rate

Financial Statements

Merger of Equals

Dividend Declaration

Management Changes

Securities Agreement

Leadership Changes

Share Purchase Agreement

Stock Amendments

Capital Structure Changes

Subsidiary Liquidation

Agreement Amendment

Stock Sale Agreement

Q3 Financial Results

Nasdaq Delisting Risk

Dividend Suspension

Nasdaq Delisting Risk

Nasdaq Compliance Issue

Accounting Firm Change

Financial Results

Annual Meeting and Manageme...

Earnings Reports

Private Placement

Earnings Reports

Management Changes

Dividend Declaration

Investor Conferences

Compliance with Nasdaq mini...

Securities Purchase Agreement

Special Meeting

Restatement of Financial St...

Earnings Reports

Bylaw Amendment

Dividend Declaration

Earnings Reports

Annual Meeting and Dividend...

Earnings Reports

Renewal of Employment Agree...

Regulation FD Disclosure

Dividend Declaration

Earnings Reports

External Links:

Cyclacel Pharmaceuticals received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement of $2.5 million, reporting only $607,000 as of December 31, 2023, and subsequently $999,000 as of June 30, 2024, leading to potential

AI Assistant

CYCLACEL PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.